Relmada Competitors

Stocks . USA . 
Stock . Relmada Therapeutics
RLMD Stock  USD 3.02  0.12  4.14%   
Relmada Therapeutics competes with Cytokinetics, Edgewise Therapeutics, Dyne Therapeutics, Third Harmonic, and Pmv Pharmaceuticals; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Relmada Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Relmada Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Relmada Therapeutics Correlation with its peers.
For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Relmada Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.142.846.87
Details
Intrinsic
Valuation
LowRealHigh
0.634.668.69
Details
Naive
Forecast
LowNextHigh
0.063.137.17
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.662.873.08
Details

Relmada Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Relmada Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Relmada and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Relmada Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RVMD
+ 0.8
DICE
RVMD
+ 0.77
EWTX
RVMD
+ 0.67
PMVP
PMVP
+ 0.63
DICE
PMVP
+ 0.62
EWTX
KRTX
+ 0.58
EWTX
  
High negative correlations   
RVMD
- 0.64
DYN
DYN
- 0.63
DICE
DYN
- 0.53
EWTX
PRDS
- 0.49
CYTK
PMVP
- 0.39
DYN
DICE
- 0.38
CYTK

Risk-Adjusted Indicators

There is a big difference between Relmada Stock performing well and Relmada Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Relmada Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Relmada Therapeutics Competitive Analysis

The better you understand Relmada Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Relmada Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Relmada Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
RLMD CYTK DICE EWTX KRTX DYN THRD PMVP RVMD PRDS
 4.14 
 3.02 
Relmada
 0.69 
 51.86 
Cytokinetics
 0.62 
 46.97 
Dice
 2.48 
 33.00 
Edgewise
 0.71 
 203.11 
Karuna
 1.67 
 30.61 
Dyne
 2.67 
 12.76 
Third
 1.25 
 1.62 
Pmv
 1.25 
 57.85 
Revolution
 0.47 
 2.14 
Pardes
Market Volatility
(90 Days Market Risk)
Relatively risky
Very steady
Very steady
Not too volatile
Very steady
Not too volatile
Moderately volatile
Slightly risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Insignificant
Very Weak
Very Weak
Good
Very Weak
Very Weak
Insignificant
Weak
Solid
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Quite High
Below Average
Dangerous
Below Average
Dangerous
Low
Low
Average
Low
Dangerous
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Not Rated
Strong Hold
Not Rated
Cautious Hold
Strong Sell
Cautious Hold
Buy
Not Rated
Current Ratio
11.4
9.01
23.61
27.49
17.77
11.63
23.59
24.76
7.6
20.84
Net Asset
97.55 M
824.32 M
593.98 M
340.04 M
1.34 B
165.08 M
277.71 M
252.15 M
2.06 B
200.62 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
4.91 M
(456.68 M)
(83.01 M)
(112.81 M)
(493.08 M)
(233.48 M)
(30.79 M)
(78.88 M)
(430.58 M)
(99.82 M)
Current Valuation
37.01 M
5.9 B
2.27 B
2.64 B
11.35 B
2.42 B
282.26 M
(85.74 M)
8.27 B
(22.1 M)
Price To Book
1.91
60.31
5.91
6.39
10.05
4.42
1.95
0.42
6.21
0.37
Operating Margin
N/A
-304.11
N/A
N/A
-755.64
N/A
N/A
N/A
-845.95
N/A
Retained Earnings
(560.9 M)
(2.11 B)
(187.59 M)
(244.76 M)
(997.89 M)
(632.51 M)
(114.22 M)
(310 M)
(1.14 B)
(148.16 M)
Current Asset
9.3 M
113.11 M
N/A
N/A
6.24 M
1.93 B
N/A
N/A
N/A
N/A
Beta
0.42
0.78
N/A
0.15
1.15
1.1
2.86
1.48
1.4
0.42
Number Of Employees
20
423
71
108
339
173
51
63
490
57
Shares Outstanding
30.17 M
118.01 M
47.76 M
94.69 M
38.2 M
101.77 M
45.06 M
51.75 M
168.22 M
62.01 M
Cash Flow From Operations
(51.66 M)
(414.33 M)
(64.32 M)
(91.95 M)
(385.82 M)
(188.16 M)
(20.43 M)
(55.66 M)
(350.57 M)
(71.98 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
12.19 M
755.77 M
13.27 M
5.41 M
16.69 M
27.41 M
3.95 M
13.29 M
87.94 M
N/A
Return On Equity
-1.0
-5.72
-0.22
-0.32
-0.36
-0.69
-0.14
-0.24
-0.47
-0.4
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-1.6
Return On Asset
-0.59
-0.3
-0.14
-0.22
-0.25
-0.4
-0.11
-0.2
-0.29
-0.26
Number Of Shares Shorted
1.15 M
14.59 M
4.88 M
6.39 M
1.97 M
10.15 M
3.13 M
846.9 K
16.35 M
874.35 K
Book Value Per Share
2.84
-0.12
11.89
5.18
32.94
6.93
6.59
3.82
9.34
2.57
Current Liabilities
3.06 M
31.65 M
N/A
N/A
8.73 M
809 M
N/A
N/A
N/A
N/A
Total Asset
97.55 M
824.32 M
593.98 M
340.04 M
1.34 B
165.08 M
277.71 M
252.15 M
2.06 B
200.62 M
Debt To Equity
0.042
2.93
0.05
0.007
0.015
0.11
7.81
0.045
0.13
N/A
Short Ratio
4.52
12.73
1.26
7.89
3.6
9.94
17.82
3.93
10.58
1.09
Target Price
12.0
80.56
49.83
45.86
324.17
50.82
19.0
5.8
71.43
1.25
Shares Owned By Institutions
46.06
99.5
96.85
99.54
86.32
99.52
92.4
80.89
97.87
72.05
Market Capitalization
91.13 M
6.16 B
2.27 B
3.12 B
12.6 B
3.17 B
590.72 M
83.83 M
9.85 B
133.95 M
Price To Earning
-1.27
-37.76
N/A
3.45
-19.88
35.58
23.13
N/A
N/A
N/A
Price To Earnings To Growth
N/A
-0.42
0.84
N/A
1.46
0.19
N/A
-0.31
N/A
N/A
Price To Sales
N/A
1914.47
699.0
N/A
19264.95
N/A
N/A
N/A
13280.71
N/A
Net Income
(98.79 M)
(526.24 M)
(83.89 M)
(100.16 M)
(433.68 M)
(235.94 M)
(30.82 M)
(68.96 M)
(436.37 M)
(96.63 M)
Earnings Per Share
-2.86
-5.38
-2.17
-1.5
-11.74
-3.58
-0.97
-1.0
-3.66
-1.28
Shares Owned By Insiders
8.04
0.5
3.15
0.46
4.98
0.48
9.04
2.3
2.13
13.47
Revenue
N/A
7.53 M
N/A
N/A
654 K
N/A
N/A
N/A
11.58 M
N/A
Working Capital
85.31 M
525.37 M
562.61 M
310.23 M
1.25 B
78.28 M
267.03 M
193.38 M
1.74 B
179.98 M
Cash And Equivalents
211.96 M
586.03 M
282.22 M
248.4 M
407.41 M
291.84 M
112.73 M
277.43 M
461.43 M
228.6 M
Cash Per Share
7.05
6.22
7.39
4.99
13.6
5.64
25.53
6.08
5.26
3.67
Gross Profit
N/A
(146.22 M)
(56.08 M)
N/A
10.64 M
N/A
N/A
N/A
(217.69 M)
N/A
Day Typical Price
2.96
52.14
46.88
32.95
203.52
30.54
12.68
1.63
58.19
2.13
Accumulation Distribution
0.0945
0.0189
0.0072
0.0329
0.0221
0.0499
0.11
0.0479
0.0335
0.0093
Market Facilitation Index
0.29
1.0
0.34
1.1
4.56
1.56
1.48
0.08
1.99
0.02
Daily Balance Of Power
0.4138
(0.36)
0.8529
0.7273
(0.32)
(0.33)
(0.24)
0.25
(0.37)
0.5
Period Momentum Indicator
0.12
(0.36)
0.29
0.8
(1.46)
(0.52)
(0.35)
0.02
(0.73)
0.01
Rate Of Daily Change
1.04
0.99
1.01
1.02
0.99
0.98
0.97
1.01
0.99
1.0
Day Median Price
2.93
52.28
46.84
32.92
203.72
30.51
12.64
1.63
58.36
2.13
Price Action Indicator
0.16
(0.60)
0.27
0.48
(1.34)
(0.16)
(0.06)
N/A
(0.87)
0.015
Relative Strength Index
35.62
74.02
84.39
58.48
32.67
30.42
65.64
67.0
82.55
45.13
Coefficient Of Variation
1757.2
(3,524)
765.93
699.23
3440.45
(1,273)
2085.05
4257.72
509.77
730.05
Mean Deviation
2.66
1.93
2.09
3.41
1.44
3.08
3.36
1.56
1.99
1.7
Jensen Alpha
0.2582
(0.30)
0.6199
0.7131
0.0265
(0.74)
(0.09)
(0.03)
0.3444
0.3665
Total Risk Alpha
(0.45)
(0.50)
(0.19)
(0.19)
(0.27)
(1.33)
(0.55)
(0.35)
0.0636
(0.09)
Sortino Ratio
0.0309
N/A
0.2923
0.2685
(0.05)
N/A
0.0162
(0.03)
0.1494
0.1172
Downside Variance
8.51
N/A
3.12
12.11
3.04
N/A
24.0
5.96
5.69
4.53
Standard Deviation
4.0
2.53
5.01
7.49
1.92
5.38
4.53
2.39
2.52
2.83
Kurtosis
4.69
0.8171
44.89
41.25
1.35
15.91
1.62
3.2
0.0616
11.81
Potential Upside
7.47
3.52
5.66
6.65
3.38
6.03
8.35
3.75
4.81
4.28
Treynor Ratio
(0.68)
(0.05)
3.47
0.3885
0.3034
(0.18)
0.0877
0.0808
0.4422
4.6
Maximum Drawdown
21.75
14.08
37.64
61.02
10.01
32.53
25.76
13.98
10.95
15.31
Variance
16.0
6.41
25.06
56.17
3.69
28.98
20.48
5.7
6.34
7.98
Market Risk Adjusted Performance
(0.67)
(0.04)
3.48
0.3985
0.3134
(0.17)
0.0977
0.0908
0.4522
4.61
Risk Adjusted Performance
0.0516
(0.01)
0.1083
0.1183
0.0282
(0.05)
0.045
0.0248
0.1569
0.112
Skewness
1.71
(0.19)
6.18
5.73
0.8553
(2.35)
(0.43)
0.797
(0.05)
2.43
Semi Deviation
2.79
N/A
1.14
2.67
1.67
N/A
4.79
1.99
2.0
1.66
Information Ratio
0.0225
(0.08)
0.1031
0.1247
(0.04)
(0.10)
0.0176
(0.03)
0.1415
0.0883
Value At Risk
(4.75)
(4.15)
(2.91)
(4.64)
(2.71)
(5.63)
(6.74)
(3.64)
(3.24)
(2.59)
Expected Short fall
(3.16)
N/A
(2.68)
(3.91)
(1.46)
N/A
(3.30)
(1.90)
(2.17)
(2.32)
Downside Deviation
2.92
N/A
1.77
3.48
1.74
N/A
4.9
2.44
2.39
2.13
Semi Variance
7.77
N/A
1.29
7.15
2.8
N/A
22.95
3.97
3.98
2.75

Relmada Therapeutics Competition Performance Charts

Five steps to successful analysis of Relmada Therapeutics Competition

Relmada Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Relmada Therapeutics in relation to its competition. Relmada Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Relmada Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Relmada Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Relmada Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Relmada Therapeutics position

In addition to having Relmada Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Currency Funds Thematic Idea Now

Currency Funds
Currency Funds Theme
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:
How To Invest In Relmada
Details
Is Relmada Stock a good investment?
Details
What is Relmada Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Relmada Therapeutics Correlation with its peers.
For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY